← Therapeutics
Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry
HG205 RNA base-editing therapy by HuidaGene
Also known as: HG205, SOUND, HG20501, OTOF-p.Q829X, NCT06025032
HuidaGene Therapeutics Co., Ltd.
Company
HuidaGene Therapeutics Co., Ltd.
Program Type
Therapeutic
Modality
RNA Therapy
Stage
Early Phase 1
Status
Discontinued
Target Gene
OTOF
Route / Mode
Intracochlear injection
Confidence
88%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-09
Geography
China
Population
pediatric, genetic, otof, rna-editing
Trial IDs
1
Mechanism
CRISPR/Cas13 RNA base-editing therapy delivered by unilateral intracochlear injection for OTOF p.Q829X mutation-associated hearing loss.
Indications
Notes
Verified as a HuidaGene-sponsored HG205 RNA base-editing study. ClinicalTrials.gov lists the study as withdrawn with zero enrolled participants because HuidaGene stopped the program due to lack of patients in China.
Evidence & Sources
1 structured sourcesclinicaltrials
Supports: canonicalName, aliases, company, allCompanies, modality, stage, status, route...
IDs: NCT06025032, HG20501, HG205
Key Events
2023-09-06
Clinical Trials (1)
Data Checks
withdrawn-zero-enrolledprogram-stopped-by-sponsor
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2